You can narrow down the results using the filters
-
Combined Habit Reversal Training and Acceptance and Commitment Therapy for Treatment of Tics in Tourette Syndrome
Tourette Syndrome (TS) is characterised by sudden, rapid and recurrent motor and vocal tics that cause significant disruptions in social and occupational functioning. Habit Reversal Training (HRT) is a behavioural treatment for tics that has received substantial empirical support for tic reduction in individuals with diagnosed Tourette Syndrome (Dutta & Cavanna, 2013). HRT focuses on increasing an individual’s awareness of tics, followed by training in performing a physically competing response (Woods, 2001). Recent research on related habit disorders, however, has indicated that treatments targeting experiential avoidance, referred to as “psychological inflexibility”, might be useful adjuncts to HRT (Franklin, Best, Wilson, Loew & Compton, 2011). Acceptance and Commitment Therapy (ACT) targets experiential avoidance by aiming to modify an individual’s attempts to control unwanted private experiences and therefore focuses on promoting acceptance of unpleasant thoughts, feelings and urges. For this reason, ACT may serve as a useful addition to HRT protocols, particularly in addressing tic-related urges and the associated unpleasant thoughts and feelings that may not be remediated by HRT. The current pilot study aims to investigate the effectiveness of a combined HRT/ACT protocol in the treatment of tics in adults. It is hypothesised that this treatment will not only reduce tic symptoms but result in positive improvements in quality of life (QoL), work/social adjustment, mood, stress and anxiety. Participants will receive ten weekly sessions of therapy in accordance with a combined HRT/ACT protocol. Two booster sessions will be provided at 1 and 2 months following completion of the eight-week treatment program. Assessments will be completed before and immediately after the eight-week course of treatment, and again at 3, 6, 9 and 12-months post-treatment to assess for any maintained improvements.
-
A trial to assess the retinal function of the eye when using a novel contact lens for myopia management
The purpose of this study is to assess the retinal function and axial length of a prototype contact lens with a line edge pattern compared to a commercially available single vision contact lens.
-
A Single-center, 2-arm Interventional Study to Determine the Association between the Gut Microbiome and the Pharmacokinetic Profile of Ibrutinib in Healthy Adult Volunteers.
The gut and tumour microbiome are known to metabolize drugs through various mechanisms resulting in degradation or modification of the drug's chemical structure which can lead to decreased drug bioavailability and effectiveness. Conversely, certain gut microbiome-derived molecules can enhance the absorption and efficacy of drugs. Ibrutinib is an example of an orally administered cancer drug (typically used to treat breast cancer) with variable pharmacokinetics which contributes to both lack of efficacy and increased toxicity. This study aims to assess how the gut microbiome can influence the pharmacokinetics of Ibrutinib in healthy adult volunteers. Who is it for? You may be eligible for this study if you are a male or female adult aged 18 to 65 years and are in good general health without a clinically significant medical history. People who have been diagnosed with cancer will not be eligible for this study. Study details Participants who choose to enrol in this study will firstly undergo a series of physical assessments, including blood tests, to ensure that they are suitable to be included in the study. Participants who are found to be suitable will be asked to stay at the research unit for up to 3 days. Participants will be asked to provide a stool sample prior to being given a single oral dose of Ibrutinib. After receiving the Ibrutinib, participants will then be asked to provide a series of blood samples over the next 2 days, and will also be asked to provide a second stool sample for analysis. At the end of the third day, participants will be allowed to return home but will be asked to contact the study team if they experience any side effects. It is hoped this research will determine any impact that different biological features such as the gut microbiome have on the ability to absorb Ibrutinib (chemotherapy) treatment. These results may then inform the usefulness of Ibrutinib as a treatment for patients with breast cancer.
-
Single-center, 2-arm Interventional Study to Determine the Association between the Gut Microbiome and the Pharmacokinetic Profile of Palbociclib in Healthy Female Volunteers.
The gut and tumour microbiome are known to metabolize drugs through various mechanisms resulting in degradation or modification of the drug's chemical structure which can lead to decreased drug bioavailability and effectiveness. Conversely, certain gut microbiome-derived molecules can enhance the absorption and efficacy of drugs. Palbociclib is an example of an orally administered cancer drug (typically used to treat breast cancer) with variable pharmacokinetics which contributes to both lack of efficacy and increased toxicity. This study aims to assess how the gut microbiome can influence the pharmacokinetics of palbociclib in healthy adult volunteers. Who is it for? You may be eligible for this study if you are a female adult aged 18 to 65 years and are in good general health without a clinically significant medical history. People who have been diagnosed with cancer will not be eligible for this study. Study details Participants who choose to enrol in this study will firstly undergo a series of physical assessments, including blood tests, to ensure that they are suitable to be included in the study. Participants who are found to be suitable will be asked to stay at the research unit for up to 3 days. Participants will be asked to provide a stool sample prior to being given a single oral dose of palbociclib. After receiving the palbociclib, participants will then be asked to provide a series of blood samples over the next 2 days, and will also be asked to provide a second stool sample for analysis. At the end of the third day, participants will be allowed to return home but will be asked to contact the study team if they experience any side effects. It is hoped this research will determine any impact that different biological features such as the gut microbiome have on the ability to absorb palbociclib (chemotherapy) treatment. These results may then inform the usefulness of palbociclib as a treatment for patients with breast cancer.
-
Feasibility and clinical accuracy of novel robot-assisted, remotely-performed abdominal ultrasound examination
This research study aims to investigate and establish the feasibility, clinical accuracy of remotely-performed, robot-assisted abdominal ultrasound examination performed by general sonographers.
-
Assessing the acceptability, appropriateness, and feasibility of a group therapy program for people with stage III melanoma (MELGROUP): a pilot study
This pilot study is assessing the acceptability, appropriateness, and feasibility of a group therapy program for people with stage III melanoma at Melanoma Institute Australia. Who is it for? You may be eligible for this trial if you are aged over 18 years and have a diagnosis of stage III melanoma. Study details: Group therapy has been helpful to people diagnosed with cancer as it can reduce feelings of isolation that are often experienced following a diagnosis of cancer by increasing social connection to people with similar experiences, while also providing people with tools and strategies to help address difficult emotions or thoughts. Thus, Melanoma Institute Australia have created a new group therapy program for people diagnosed with stage III melanoma, and the aim of this study to ensure it is acceptable and appropriate to participants. There will be a total of 8 sessions that occur every two weeks (fortnightly) either in-person at Melanoma Institute Australia or online via a videoconferencing platform (Zoom). Sessions will be two hours in length and will be focused on discussing skills and strategies that may be helpful in coping with difficult situations/emotions associated with a diagnosis of stage III melanoma. Groups will consist of approximately 8 people recently diagnosed with stage III melanoma. Information from this study will be used to design a larger study to test how helpful it is with the aim or implementing MELGROUP therapy into routine clinical practice in the future.
-
The GLOW Trial: implementing Guidelines for hypothermia prevention with Local adaptation to keep periOperative patients Warm.
Over 1.2 million Australian patients are at risk of experiencing perioperative hypothermia (heat loss to below 36°C) annually, with a cost of over $1.2 billion to the Australian health care system. Perioperative hypothermia is associated with numerous adverse outcomes including increased wound infection, increased blood loss, longer hospital stays, patient discomfort and poor surgical experience. Prevention involves consistent temperature monitoring and appropriate use of warming strategies throughout surgery. However, in Australia, temperature monitoring during surgery occurs in around 20% of procedures and rates of perioperative hypothermia remain high at approximately 27% of patients. Our trial will evaluate practice recommendations and an implementation strategy for sustainable improvement in perioperative hypothermia prevention in Australian hospitals.
-
Efficacy and safety of prehospital fibrinogen early in severe trauma study: A feasibility phase II study (PRE-FEISTY II) (Stage 1).
This study aims to investigate the feasibility and effect of administering fibrinogen concentrate in the setting of severe traumatic bleeding in the prehospital setting, This is being done to evaluate the possibility of conducting a prehospital arm of the forthcoming FEISTY II study.
-
Clinical Performance of Coronavirus (COVID-19) Antigen Rapid Test Kits for the detection of COVID-19 variants in clinical samples from people aged 7-75 years
Expand description -
A comparison of health complications arising 12 months after a PCR-positive test for COVID-19, influenza, and respiratory syncytial virus.
This research project aims to: a) To examine the risks of subsequent health complications (determined by ICD-10AM code) in the 12 months following COVID-19, influenza or RSV infection, compared with a control group (no recent evidence of COVID-19 or influenza infection). b) inform Queensland Health about the potential scale of post-viral impacts arising from COVID-19 or influenza, and any system-wide response that may be required. The Project Team is part of the Office of the Chief health Officer in Queensland Health, which accesses the Notifiable Conditions System. The system houses information on COVID-19, influenza and RSV-positive PCRs.